Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Conferences
Guide to authors
Online submissionOnline submission
Permissions
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
naturereprints
About this site
For librarians
 
NPG Resources
Bioentrepreneur
Nature Reviews Drug Discovery
Nature
Nature Medicine
Nature Genetics
Nature Reviews Genetics
Nature Methods
Nature Chemical Biology
news@nature.com
Clinical Pharmacology & Therapeutics
Nature Conferences
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Biotechnology  21, 652 - 659 (2003)
Published online: 5 May 2003; Corrected online: 30 May 2003 | doi:10.1038/nbt822


There is a Corrigenda (July 2003) associated with this Article.

High-throughput engineering of the mouse genome coupled with high-resolution expression analysis

David M Valenzuela1, Andrew J Murphy1, 3, David Frendewey1, 3, Nicholas W Gale1, 3, Aris N Economides1, 3, Wojtek Auerbach1, William T Poueymirou1, Niels C Adams1, Jose Rojas1, Jason Yasenchak1, Rostislav Chernomorsky1, Marylene Boucher1, Andrea L Elsasser1, Lakeisha Esau1, Jenny Zheng1, Jennifer A Griffiths1, Xiaorong Wang1, Hong Su1, Yingzi Xue1, Melissa G Dominguez1, Irene Noguera1, Richard Torres1, Lynn E Macdonald1, A Francis Stewart2, Thomas M DeChiara1 & George D Yancopoulos1

1  Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Road, Tarrytown, New York 10591, USA.

2  BIOTEC, Technische Universitat Dresden, Dresden, Germany 01307.

3  These authors contributed equally to this work.

Correspondence should be addressed to George D Yancopoulos velocigene@regeneron.com
One of the most effective approaches for determining gene function involves engineering mice with mutations or deletions in endogenous genes of interest. Historically, this approach has been limited by the difficulty and time required to generate such mice. We describe the development of a high-throughput and largely automated process, termed VelociGene, that uses targeting vectors based on bacterial artificial chromosomes (BACs). VelociGene permits genetic alteration with nucleotide precision, is not limited by the size of desired deletions, does not depend on isogenicity or on positive−negative selection, and can precisely replace the gene of interest with a reporter that allows for high-resolution localization of target-gene expression. We describe custom genetic alterations for hundreds of genes, corresponding to about 0.5−1.0% of the entire genome. We also provide dozens of informative expression patterns involving cells in the nervous system, immune system, vasculature, skeleton, fat and other tissues.
*Note: In the author list of the AOP version of this article, the name of author Rostislav Chernomorsky was misspelled Rostislav Chernomorski. This has been corrected in the online and print versions of the article.

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

naturejobs

Competing financial interests
Figures & Tables
Supplementary info
See also: News and Views by Rossant
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Biotechnology
ISSN: 1087-0156
EISSN: 1546-1696
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | Conferences | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2003 Nature Publishing Group | Privacy policy